CisEto | | | Every 3 weeks, or after nadir, normal renal function and diuretics are mandatory |
Cisplatin | 80 mg·m−2 | i.v. d1 |
Etoposide | 100 mg·m−2 | i.v. d1–d3 |
ACO-I after Livingston and Seeber | | | Every 3 weeks; vincristine dosage has to be adjusted to age; >60 years reduce to 1 mg·m−2 |
Adriamycin | 60 mg·m−2 | i.v. d1 |
Cyclophosphamide | 750 mg·m−2 | i.v. d1 |
Vincristine | 2 mg·m−2 | i.v. d1/d8/d16 |
ACE combination after Klastersky | | | |
Adriamycin | 45 mg·m−2 | i.v. d1 | |
Cyclophosphamide | 1000 mg·m−2 | i.v. d1 | |
Etoposide | 80 mg·m−2 | i.v. d1–d3 | Every 3 weeks. |
EpiCO therapy after Drings | | | Every 3 weeks; vincristine dosage has to be adjusted to age; >60 years reduce to 1 mg·m−2 |
Epirubicin | 70 mg·m−2 | i.v. d1 |
Cyclophosphamide | 1000 mg·m−2 | i.v. d1 |
Vincristine | 2 mg·m−2 | i.v. d1/d8/d16 |
Carboplatin/etoposide | | | Every 3 weeks, or after nadir, normal renal function and diuretics are mandatory |
Carboplatin | AUC 5 | i.v. d1 |
Etoposide | 100 mg·m−2 | i.v. d1-d3 |
Paclitaxel/etoposide/carboplatin | | | Every 3 weeks, steroids to prevent anaphylactic crisis after administration of paclitaxel is mandatory |
Paclitaxel | 175 mg·m−2 | i.v. for 3 h |
Carboplatin | AUC 5 | d4 |
Etoposide | I–III: 100 mg·m−2 | i.v. d4 |
| IV: 100 mg·m−2 | d1–d3 |
Cisplatin/irinotecan | | | Atropine 0.25 mg 1/2 h before irinotecan s.c. Every 4 weeks and/or after nadir; diarrhoea is common |
Cisplatin | 60 mg·m−2 | i.v. d1 |
Irinotecan | 60 mg·m−2 | i.v. d 1, 8,15 |
Topotecan (second-line) | | | |
Topotecan | 1.25 mg·m−2 with subsequent dose adjustment according to haematological toxicity | i.v. d 1–5 | Every 3 weeks and/or after reaching normal laboratory values |